Valeo’s
Canadian Roots

 

Rooted in specialty pharma, Valeo is growing Canadian healthcare by licensing and acquiring Canadian rights to commercial stage, innovative, and proprietary drugs.

Founded in 2003, Valeo Pharma originally focused on dermatology and Hospital specialty, until 2014 when it sold its entire product portfolio to Valeant.

Management and a growing base of employees (100+) is now refocused on large new therapeutic areas and commercializing drugs in Canada.

Publicly traded since

February 2019

Listed on the TSX in

March 2022

Publicly traded since

February 2019

Listed on the TSX in

March 2022

Areas of Focus

Valeo’s company growth is coming by way of these therapeutic areas.

Within these areas, we now have 9 commercialized products and are continuously looking to add more.

3

Business Units

9

Commercialized Products

This focused growth plan has helped deliver significant growth over the last few years.

!

99%

CAGR for revenues over the last 3 years

Valeo’s Fully Integrated
Capabilities

 

Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization